Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Meletios A Dimopoulos; Pieter Sonneveld; Salomon Manier; Annette Lam; Tito Roccia; Jordan M. Schecter; Patricia Cost; Lida Pacaud; Abbey E. Poirier; Gabriel Tremblay; Tommy Lan; Satish Valluri; Shaji Kumar

doi:10.1186/s12885-024-12263-0

Related publications

Article2017

Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Meletios A Dimopoulos, Pieter Sonneveld, Hareth Nahi, Shaji Kumar, Mahmoud Hashim, Margarita Kulakova, Marta Duran, Bart Heeg, Annette Lam, Lindsay Dearden

Article2011

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma

Meletios A Dimopoulos, M. A. Hussein, Arlene S. Swern, Daniela Weber

Article2022

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel

Article2020

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

Xiaoyu Yan, Xu Steven Xu, Katja Weisel, María‐Victoria Mateos, Pieter Sonneveld, Meletios A Dimopoulos, Saad Z. Usmani, Nizar J. Bahlis, Thomas A. Puchalski, Jon Ukropec, Kevin M. Bellew, Ming Qi, Steven Sun, Honghui Zhou

Article2016

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Flora Zagouri, Μαρία Ρούσσου, Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Despoina Kalapanida, Dimitrios Christoulas, Magdalini Migkou, Evangelos Terpos, Meletios A Dimopoulos